Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

Salvatore Petta, Luigi Elio Adinolfi, Anna Ludovica Fracanzani, Francesca Rini, Rosalia Caldarella, Vincenza Calvaruso, Calogero Cammà, Marcello Ciaccio, Vito Di Marco, Stefania Grimaudo, Anna Licata, Aldo Marrone, Riccardo Nevola, Rosaria Maria Pipitone, Antonio Pinto, Luca Rinaldi, Daniele Torres, Antonino Tuttolomondo, Luca Valenti, Silvia FargionAntonio Craxì

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background and Aims: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. Materials and methods: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickness (IMT), carotid thickening (IMT ≥1 mm) and carotid plaques, defined as focal thickening of ≥1.5 mm at the level of the common carotid, were evaluated by ultrasonography (US) at baseline and 9–12 months after the end of therapy. Fifty-six percent of patients were male, mean age 63.1 ± 10.4 years, and 65.9% had compensated cirrhosis. One in five had diabetes, 14.3% were obese, 41.8% had arterial hypertension and 35.2% were smokers. At baseline, mean IMT was 0.94 ± 0.29 mm, 42.8% had IMT ≥1 mm, and 42.8% had carotid plaques. Results: All patients achieved a 12-week sustained virological response. IMT significantly decreased from baseline to follow-up (0.94 ± 0.29 mm vs. 0.81 ± 0.27, p <0.001). Consistently, a significant reduction in the prevalence of patients with carotid thickening from baseline to follow-up was observed (42.8% vs. 17%, p <0.001), while no changes were reported for carotid plaques (42.8% vs. 47.8%, p = 0.34). These results were confirmed in subgroups of patients stratified for cardiovascular risk factors and liver disease severity. Conclusion: HCV eradication by DAA improves carotid atherosclerosis in patients with severe fibrosis with or without additional metabolic risk factors. The impact of this improvement in the atherosclerotic burden in terms of reduction of major cardiovascular outcomes is worth investigating in the long term. Lay summary: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. The improvement in intima-media thickness and carotid thickening was confirmed after stratification for severity of liver disease and cardiovascular risk factors. Hepatitis C virus eradication by direct-acting antiviral agents also lead to improvement in glucose homeostasis and increased cholesterol levels.

Original languageEnglish
Pages (from-to)18-24
Number of pages7
JournalJournal of Hepatology
Volume69
Issue number1
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Carotid Artery Diseases
Hepacivirus
Liver Cirrhosis
Antiviral Agents
Fibrosis
Carotid Intima-Media Thickness
Liver Diseases
Virus Diseases
Ultrasonography
Homeostasis
Cholesterol
Guidelines
Hypertension
Glucose

Keywords

  • Atherosclerosis
  • DAA
  • HCV
  • SVR

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. / Petta, Salvatore; Adinolfi, Luigi Elio; Fracanzani, Anna Ludovica; Rini, Francesca; Caldarella, Rosalia; Calvaruso, Vincenza; Cammà, Calogero; Ciaccio, Marcello; Di Marco, Vito; Grimaudo, Stefania; Licata, Anna; Marrone, Aldo; Nevola, Riccardo; Pipitone, Rosaria Maria; Pinto, Antonio; Rinaldi, Luca; Torres, Daniele; Tuttolomondo, Antonino; Valenti, Luca; Fargion, Silvia; Craxì, Antonio.

In: Journal of Hepatology, Vol. 69, No. 1, 01.07.2018, p. 18-24.

Research output: Contribution to journalArticle

Petta, S, Adinolfi, LE, Fracanzani, AL, Rini, F, Caldarella, R, Calvaruso, V, Cammà, C, Ciaccio, M, Di Marco, V, Grimaudo, S, Licata, A, Marrone, A, Nevola, R, Pipitone, RM, Pinto, A, Rinaldi, L, Torres, D, Tuttolomondo, A, Valenti, L, Fargion, S & Craxì, A 2018, 'Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis', Journal of Hepatology, vol. 69, no. 1, pp. 18-24. https://doi.org/10.1016/j.jhep.2018.02.015
Petta, Salvatore ; Adinolfi, Luigi Elio ; Fracanzani, Anna Ludovica ; Rini, Francesca ; Caldarella, Rosalia ; Calvaruso, Vincenza ; Cammà, Calogero ; Ciaccio, Marcello ; Di Marco, Vito ; Grimaudo, Stefania ; Licata, Anna ; Marrone, Aldo ; Nevola, Riccardo ; Pipitone, Rosaria Maria ; Pinto, Antonio ; Rinaldi, Luca ; Torres, Daniele ; Tuttolomondo, Antonino ; Valenti, Luca ; Fargion, Silvia ; Craxì, Antonio. / Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. In: Journal of Hepatology. 2018 ; Vol. 69, No. 1. pp. 18-24.
@article{73f357cbafb74bf09d2c7bedc9813df9,
title = "Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis",
abstract = "Background and Aims: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. Materials and methods: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickness (IMT), carotid thickening (IMT ≥1 mm) and carotid plaques, defined as focal thickening of ≥1.5 mm at the level of the common carotid, were evaluated by ultrasonography (US) at baseline and 9–12 months after the end of therapy. Fifty-six percent of patients were male, mean age 63.1 ± 10.4 years, and 65.9{\%} had compensated cirrhosis. One in five had diabetes, 14.3{\%} were obese, 41.8{\%} had arterial hypertension and 35.2{\%} were smokers. At baseline, mean IMT was 0.94 ± 0.29 mm, 42.8{\%} had IMT ≥1 mm, and 42.8{\%} had carotid plaques. Results: All patients achieved a 12-week sustained virological response. IMT significantly decreased from baseline to follow-up (0.94 ± 0.29 mm vs. 0.81 ± 0.27, p <0.001). Consistently, a significant reduction in the prevalence of patients with carotid thickening from baseline to follow-up was observed (42.8{\%} vs. 17{\%}, p <0.001), while no changes were reported for carotid plaques (42.8{\%} vs. 47.8{\%}, p = 0.34). These results were confirmed in subgroups of patients stratified for cardiovascular risk factors and liver disease severity. Conclusion: HCV eradication by DAA improves carotid atherosclerosis in patients with severe fibrosis with or without additional metabolic risk factors. The impact of this improvement in the atherosclerotic burden in terms of reduction of major cardiovascular outcomes is worth investigating in the long term. Lay summary: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. The improvement in intima-media thickness and carotid thickening was confirmed after stratification for severity of liver disease and cardiovascular risk factors. Hepatitis C virus eradication by direct-acting antiviral agents also lead to improvement in glucose homeostasis and increased cholesterol levels.",
keywords = "Atherosclerosis, DAA, HCV, SVR",
author = "Salvatore Petta and Adinolfi, {Luigi Elio} and Fracanzani, {Anna Ludovica} and Francesca Rini and Rosalia Caldarella and Vincenza Calvaruso and Calogero Camm{\`a} and Marcello Ciaccio and {Di Marco}, Vito and Stefania Grimaudo and Anna Licata and Aldo Marrone and Riccardo Nevola and Pipitone, {Rosaria Maria} and Antonio Pinto and Luca Rinaldi and Daniele Torres and Antonino Tuttolomondo and Luca Valenti and Silvia Fargion and Antonio Crax{\`i}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jhep.2018.02.015",
language = "English",
volume = "69",
pages = "18--24",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

AU - Petta, Salvatore

AU - Adinolfi, Luigi Elio

AU - Fracanzani, Anna Ludovica

AU - Rini, Francesca

AU - Caldarella, Rosalia

AU - Calvaruso, Vincenza

AU - Cammà, Calogero

AU - Ciaccio, Marcello

AU - Di Marco, Vito

AU - Grimaudo, Stefania

AU - Licata, Anna

AU - Marrone, Aldo

AU - Nevola, Riccardo

AU - Pipitone, Rosaria Maria

AU - Pinto, Antonio

AU - Rinaldi, Luca

AU - Torres, Daniele

AU - Tuttolomondo, Antonino

AU - Valenti, Luca

AU - Fargion, Silvia

AU - Craxì, Antonio

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background and Aims: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. Materials and methods: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickness (IMT), carotid thickening (IMT ≥1 mm) and carotid plaques, defined as focal thickening of ≥1.5 mm at the level of the common carotid, were evaluated by ultrasonography (US) at baseline and 9–12 months after the end of therapy. Fifty-six percent of patients were male, mean age 63.1 ± 10.4 years, and 65.9% had compensated cirrhosis. One in five had diabetes, 14.3% were obese, 41.8% had arterial hypertension and 35.2% were smokers. At baseline, mean IMT was 0.94 ± 0.29 mm, 42.8% had IMT ≥1 mm, and 42.8% had carotid plaques. Results: All patients achieved a 12-week sustained virological response. IMT significantly decreased from baseline to follow-up (0.94 ± 0.29 mm vs. 0.81 ± 0.27, p <0.001). Consistently, a significant reduction in the prevalence of patients with carotid thickening from baseline to follow-up was observed (42.8% vs. 17%, p <0.001), while no changes were reported for carotid plaques (42.8% vs. 47.8%, p = 0.34). These results were confirmed in subgroups of patients stratified for cardiovascular risk factors and liver disease severity. Conclusion: HCV eradication by DAA improves carotid atherosclerosis in patients with severe fibrosis with or without additional metabolic risk factors. The impact of this improvement in the atherosclerotic burden in terms of reduction of major cardiovascular outcomes is worth investigating in the long term. Lay summary: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. The improvement in intima-media thickness and carotid thickening was confirmed after stratification for severity of liver disease and cardiovascular risk factors. Hepatitis C virus eradication by direct-acting antiviral agents also lead to improvement in glucose homeostasis and increased cholesterol levels.

AB - Background and Aims: Recent studies suggest an association between hepatitis C virus (HCV) infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct-acting antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis. Materials and methods: One hundred eighty-two consecutive patients with HCV and advanced fibrosis or compensated cirrhosis were evaluated. All patients underwent DAA-based antiviral therapy according to AISF/EASL guidelines. Intima-media thickness (IMT), carotid thickening (IMT ≥1 mm) and carotid plaques, defined as focal thickening of ≥1.5 mm at the level of the common carotid, were evaluated by ultrasonography (US) at baseline and 9–12 months after the end of therapy. Fifty-six percent of patients were male, mean age 63.1 ± 10.4 years, and 65.9% had compensated cirrhosis. One in five had diabetes, 14.3% were obese, 41.8% had arterial hypertension and 35.2% were smokers. At baseline, mean IMT was 0.94 ± 0.29 mm, 42.8% had IMT ≥1 mm, and 42.8% had carotid plaques. Results: All patients achieved a 12-week sustained virological response. IMT significantly decreased from baseline to follow-up (0.94 ± 0.29 mm vs. 0.81 ± 0.27, p <0.001). Consistently, a significant reduction in the prevalence of patients with carotid thickening from baseline to follow-up was observed (42.8% vs. 17%, p <0.001), while no changes were reported for carotid plaques (42.8% vs. 47.8%, p = 0.34). These results were confirmed in subgroups of patients stratified for cardiovascular risk factors and liver disease severity. Conclusion: HCV eradication by DAA improves carotid atherosclerosis in patients with severe fibrosis with or without additional metabolic risk factors. The impact of this improvement in the atherosclerotic burden in terms of reduction of major cardiovascular outcomes is worth investigating in the long term. Lay summary: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. The improvement in intima-media thickness and carotid thickening was confirmed after stratification for severity of liver disease and cardiovascular risk factors. Hepatitis C virus eradication by direct-acting antiviral agents also lead to improvement in glucose homeostasis and increased cholesterol levels.

KW - Atherosclerosis

KW - DAA

KW - HCV

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=85044589215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044589215&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2018.02.015

DO - 10.1016/j.jhep.2018.02.015

M3 - Article

AN - SCOPUS:85044589215

VL - 69

SP - 18

EP - 24

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -